On November 29, 2012, FDA approved a labeling change for Hepsera (adefovir dipivoxil) package insert to include the following information under Section 5.5, Coadministration with Other Products, and to Section 17.1, Patient Counseling Information/Instructions for Safe Use.
Hepsera should not be used concurrently with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disporoxil fumarate combination tablet).
Hepsera is nucleotide analogue for the treatment of chronic hepatitis B infection, manufactured by Gilead Sciences.
The complete, up-to-date Hepsera label may be viewed at Drugs@FDA.
© 2025 HealthCentral LLC. All rights reserved.
More Like This
Adverse Events & Comorbidities
No Need to Adjust for Race When Analyzing Pulmonary Function
Providing Quality HIV Care
From Provider Stigma to Chemsex: HIV Glasgow 2024 Highlights
HIV and Mental Health
Next Steps for Improving Neurocognition in Older People With HIV
Adverse Events & Comorbidities